The U.S. Food and Drug Administration today approved Eisai’s Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug. “Halaven is…
Dako, an Agilent Technologies Company, Announces Expanded FDA Approval of Complementary Diagnostic Test to Include Melanoma Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, today announced that the U.S. Food and Drug Administration (FDA) has approved the expansion of the intended use of Dako PD-L1 IHC 28-8 pharmDx to include patients…
Opdivo + Yervoy Regimen now indicated for unresectable or metastatic melanoma patients, regardless of BRAF mutational status, based on accelerated approval1 Demonstrated significantly superior progression-free survival vs. Yervoy alone in CheckMate -067 with the first and only FDA-approved combination of immune checkpoint inhibitors1,2 FDA also expands use of Opdivo as single-agent to include previously untreated BRAF mutation-positive advanced melanoma…
AbbVie and Roche’s investigational BCL-2 inhibitor venetoclax was granted priority review by the FDA for the treatment of chronic lymphocytic leukaemia (CLL) in patients, including those with p17 deletion, who received at least one prior therapy, Roche announced Tuesday. Roche chief medical officer Sandra Horning said “we look forward to working with AbbVie and health…
On January 19, 2016, the U.S. Food and Drug Administration approved ofatumumab (Arzerra Injection, Novartis Pharmaceuticals Corporation) for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL). Ofatumumab was previously approved for the treatment of previously untreated patients…
Originally published on CNN, here. Pivotal Head-To-Head ENDEAVOR Study Shows Kyprolis and Dexamethasone Doubled Progression-Free Survival Versus Velcade® (Bortezomib) and Dexamethasone Kyprolis Label Expansion Represents Critical Advancement for Patients With Relapsed or Refractory Multiple Myeloma, Offering New Option For Backbone Therapy Approval Expands Kyprolis Indication and Converts Monotherapy Indication to Full Approval. THOUSAND OAKS, Calif., Jan. 21,…
Living with CLL Orlando, FL On January 14th, FLASCO held Living with CLL Patient Education Dinner Program in Orlando, FL with support from Pharmacyclics. This was an overwhelmingly successful event with wonderful reviews from all in attendance We would like to recognize the amazing speakers that donated their time and made this program a great success. Our sincerest gratitude…
FDA Expands Label For Pembrolizumab (Keytruda® Injection, Merck Sharp & Dohme Corp) Corporate Press Release Prescribing Information Medication Guide On December 18, 2015, the U. S. Food and Drug Administration (FDA) expanded the label to include the approval of pembrolizumab (Keytruda® Injection, Merck Sharp & Dohme Corp.) for the treatment of patients with unresectable or…
J Code for KEYTRUDA® (pembrolizumab) Available KEYTRUDA has been assigned a permanent HCPCS* code, effective January 1, 2016.1 HCPCS CODE DESCRIPTOR J9271 Injection, pembrolizumab, 1 mg For dates of service prior to January 1, 2016, use the appropriate unspecified HCPCS code to bill for KEYTRUDA. If you have questions about KEYTRUDA, please contact your…
Cevallos to Assume Greater Leadership Role for Nation’s Largest Independent Hematology/Oncology Practice Fort Myers, FL – December 21, 2015 . . . Florida Cancer Specialists & Research Institute (FCS), the leading community oncology/hematology practice in the state, is pleased to announce that Sarah Cevallos has been named Chief Revenue Cycle Officer and is assuming a broad range of responsibilities…
Florida Cancer Specialists Announces Senior Management Promotions Fort Myers, FL – December 22, 2015 . . . Florida Cancer Specialists & Research Institute (FCS), the leading community oncology/hematology practice in the state, is pleased to announce the promotions of three senior leaders in the organization. Michael Essik has been promoted to Vice President of Finance;…
The U.S. Food and Drug Administration today approved Vistogard (uridine triacetate) for the emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or capecitabine, or who develop certain severe or life-threatening toxicities within four days of receiving these cancer treatments. “Treating cancer requires not only selecting which drug may…
Click here to read corporate press release The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Xalkori (crizotinib). Lung cancer is the leading cause of cancer death…
The U.S. Food and Drug Administration today approved Bridion (sugammadex) injection to reverse the effects of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide, which are used during certain types of surgery in adults. Rocuronium bromide and vecuronium bromide are neuromuscular blocking drugs that cause temporary paralysis by interfering with the transmission of nerve…
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) today announce that the U.S. Food and Drug Administration (FDA) has approved BENDEKA™, (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine. BENDEKA is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) and for the treatment…
The U.S. Food and Drug Administration approved Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD). Vonvendi is the first FDA-approved recombinant von Willebrand factor, and is approved for the on-demand (as needed) treatment and control of bleeding episodes in adults diagnosed with…
U.S. Food and Drug Administration cleared for marketing in the United States the first cooling cap to reduce hair loss (alopecia) in female breast cancer patients undergoing chemotherapy. Hair loss is a common side effect of certain types of chemotherapy, commonly associated with the treatment of breast cancer. Hair may fall out entirely, gradually, in…
Announcing the assignment of a product-specific Healthcare Common Procedure Coding System (HCPCS) code for CYRAMZA® (ramucirumab) for injection. The new code, J9308, is defined as Injection, ramucirumab, 5 mg. This code is effective January 1, 2016. Trade Name HCPCS Code1 Strength NDC* CYRAMZA J9308 Injection, ramucirumab, 5 mg 100 mg/10 mL (10 mg/mL) 500…
Florida Cancer Affiliates is adding a new medical oncologist to its staff. Dr. Madhu K. Emani will be joining the practice November 2nd and will be caring for patients in FCA’s new Trinity treatment center. Experienced in the diagnosis and treatment of a variety of cancers, Dr. Emani has extensive expertise in both Medical Oncology…
Click here to read corporate press release U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. Multiple myeloma is a form of blood cancer that occurs in infection-fighting plasma cells (a type of white…
Click here for corporate release The U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. Multiple myeloma is a form of blood cancer that occurs in infection-fighting plasma cells (a type of white…
FDA approves Lilly’s Portrazza to treat advanced squamous non-small cell lung cancer The U.S. Food and Drug Administration today approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer. Lung…
On November 23, 2015, the U. S. Food and Drug Administration approved nivolumab (Opdivo Injection, Bristol-Myers Squibb Company) for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy. The approval was based on a randomized study in which patients with advanced renal cell cancer who had received prior anti-angiogenic…
On November 20, 2015, the U.S. Food and Drug Administration approved ixazomib (NINLARO, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited) in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. Ixazomib is the first approved oral proteasome inhibitor….
Novartis receives FDA regular approval for Tafinlar® + Mekinist® to treat aggressive form of melanoma based on long-term survival data The U. S. Food and Drug Administration granted accelerated approval to trametinib and dabrafenib for use in combination in the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K…
On November 13, 2015, the U. S. Food and Drug Administration granted accelerated approval to osimertinib (TAGRISSO) once daily tablets, AstraZeneca Pharmaceuticals LP, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine…
On November 16, 2015, the U.S. Food and Drug Administration granted accelerated approval to daratumumab injection (DARZALEX, Janssen Biotech, Inc.), administered as a single agent for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are…
FDA Approves Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection The U.S. Food and Drug Administration approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of…
Brad Prechtl Named Florida Chair of CEOs Against Cancer Florida Cancer Specialists’ Chief Executive Leads the Cause in the Sunshine State Florida Cancer Specialists & Research Institute (FCS) is pleased to announce that CEO Brad Prechtl has been named Chair of the Florida Chapter of CEOs Against Cancer, a program of the American Cancer Society…
FDA Approves Genentech’s Cotellic™ (Cobimetinib) in Combination With Zelboraf® (Vemurafenib) in Advanced Melanoma Click here to read corporate press release The U.S. Food and Drug Administration approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery,…
Florida Cancer Affiliates (FCA) has added a new radiation oncologist to the practice. Kazumi Chino, M.D., joined the practice’s North Florida division and is providing radiation oncology services in Panama City. Dr. Chino has extensive training in the very latest state-of-the art radiation therapies and is board certified in Radiation Oncology. She treats the full…
U.S. Food and Drug Administration expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma, to lower the risk that the melanoma will return following surgery. Melanoma, the most aggressive type of skin cancer, is the leading cause of death from skin cancer. Melanoma…
The U.S. Food and Drug Administration today approved Imlygic (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy, for the treatment of melanoma lesions in the skin and lymph nodes. “Melanoma is a serious disease that can advance and spread to other parts of the body, where it becomes difficult to treat,” said Karen Midthun, M.D.,…
Yondelis (trabectedin) Janssen The U.S. Food and Drug Administration today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who previously received chemotherapy that contained anthracycline. According to…
The U.S. Food and Drug Administration today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy. According to the National Cancer Institute, there will be 48,960 new cases of pancreatic cancer diagnosed in the U.S. in 2015,…
Living with Myeloma Jacksonville, FL On October 15th, FLASCO held Living with Myeloma Patient Education Dinner Program in Jacksonville, FL with support from Takeda Oncology. This was an overwhelmingly successful event with over 50 patients and caregivers in attendance. We would like to recognize the amazing speakers that donated their time and added greatly to…
Rosetta Genomics Ltd. a leading developer and provider of microRNA-based and other molecular diagnostics, announces the launch of a molecular test for BRAF mutation analysis to help personalize therapy for melanoma and colon cancer patients. This newest assay will complement its broad offerings so that oncologists can optimize treatment decisions for their cancer patients. Rosetta…
On October 9, 2015, the FDA approved Opdivo (nivolumab) to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy. “The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy….
KEYTRUDA is indicated for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. This…
FDA approved an expanded indication for the Optune device to treat patients with newly-diagnosed glioblastoma multiforme (GBM), an aggressive form of brain cancer. It is given along with the chemotherapy drug temozolomide (TMZ) following standard treatments that include surgery, chemotherapy, and radiation therapy. [su_button url=”http://links.govdelivery.com/track?type=click&enid=ZWFzPTEmbWFpbGluZ2lkPTIwMTUxMDA3LjQ5OTcwNzExJm1lc3NhZ2VpZD1NREItUFJELUJVTC0yMDE1MTAwNy40OTk3MDcxMSZkYXRhYmFzZWlkPTEwMDEmc2VyaWFsPTE3MjAxMTM4JmVtYWlsaWQ9RG9yb3RoeS5HcmVlbkBmbGFzY28ub3JnJnVzZXJpZD1Eb3JvdGh5LkdyZWVuQGZsYXNjby5vcmcmZmw9JmV4dHJhPU11bHRpdmFyaWF0ZUlkPSYmJg==&&&107&&&http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm465744.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery” target=”blank” style=”flat” background=”#ff002d” color=”#fafafa” size=”5″ center=”yes” icon=”icon: hand-o-right” icon_color=”#ffffff” text_shadow=”0px…
FLASCO wishes all PAs a Happy PA week! This marks the 50th anniversary of the PA profession. Before it was a week-long event, National PA Day was first celebrated on October 6, 1987, in honor of the 20th anniversary of the first graduating class of PAs from the Duke University PA program. October 6 is…
FLASCO appreciates our partnership with Moffitt Cancer Center. Congratulations on a Successful Conference!
FCS Welcomes Visjay Patel, MD Florida Cancer Specialists & Research Institute (FCS), the leading community oncology/hematology practice in the state, is pleased to announce that Vijay Patel, MD, has joined Florida Cancer Specialists and will be seeing patients at the FCS cancer center in Gainesville at 1147 NW 64th Terrace. Dr. Patel began practicing medical…
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab), for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. Read Corporate Press Release FDA Information: U. S. Food and Drug Administration granted accelerated approval to nivolumab (Opdivo Injection, Bristol-Myers Squibb Company) in…
AdvaMed CEO Ubl to lead PhRMA Source: Modern Healthcare By Adam Rubenfire September 25, 2015 Stephen Ubl, the lead lobbyist for the medical device industry, has been named president and CEO of the Pharmaceutical Research and Manufacturers of America. Ubl, 46, has led the Advanced Medical Technology Association, or AdvaMed, a medical device trade group,…
(BUSINESS WIRE)–Merck and Pfizer announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for the investigational cancer immunotherapy avelumab* for the treatment of Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer.1,2 Each year, there are approximately 1,500 new cases of MCC diagnosed in the US.3 “We…
Welcome to ICD-10 CMS BLOG http://blog.cms.gov/2015/10/01/welcome-to-icd-10/ By Sean Cavanaugh, Deputy Administrator and Director, Center for Medicare Today, the U.S. health care system moves to the International Classification of Diseases, 10th Revision – ICD-10. We’ve tested and retested our systems in anticipation of this day, and we’re ready to accept properly coded ICD-10 claims. The change…
Bipartisan Lawmakers Send Letters to CMS Opposing Proposed Cuts to Radiation Therapy (Source: US Oncology) This week 228 bipartisan lawmakers in Congress sent three letters to the Centers for Medicare & Medicaid Services (CMS) asking the agency to reconsider proposed cuts to radiation oncology recommended in its 2016 Physician Fee Schedule (PFS) Proposed Rule. In…
Moffitt Cancer Center and Bristol-Myers Squibb Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Program NEW YORK & TAMPA, Fla., Sep 25, 2015 (BUSINESS WIRE) — Bristol-Myers Squibb Company and Moffitt Cancer Center today announced that they have entered into a collaboration agreement as part of Bristol-Myers Squibb’s Immuno-Oncology…
Courtesy Calls from First Coast Service Options First Coast has a new team (CERT Clinical Nurse Educators) making daily calls to providers across JN regarding CERT claims that have been audited by the CERT contractor and assessed with an error. Our goal in making one-to-one education calls is to provide outreach regarding specific education related…
CMS Proposes New Medicare Clinical Diagnostic Laboratory Tests Fee Schedule Proposed initiative would begin data collection process to set new payment rates WASHINGTON (September 25, 2015) – The Centers for Medicare & Medicaid Services (CMS) today announced its next step in implementing the Protecting Access to Medicare Act of 2014 (PAMA), requiring clinical laboratories…
On September 22, 2015, the U.S. Food and Drug Administration approved LONSURF® (trifluridine and tipiracil) tablets. LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF…
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial The Lancet Oncology has recently published the overall survival (OS) data from a head-to-head Phase III clinical trial. The study evaluated a lung cancer treatment as a potential option for patients with…
“Find a Clinical Trial for Oral, Head and Neck Cancer” Call toll-free 844-432-3888 (Mon-Fri, 9 am -5 pm ET) SPOHNC is pleased to introduce EmergingMed’s Clinical Trial Navigation Service. We want you to be aware of all of your treatment options. SPOHNC has partnered with EmergingMed to offer you a way to take action. The…
FDA Approves New Oral Medication to Treat Patients with Advanced Colorectal Cancer The U.S. Food and Drug Administration today approved Taiho Oncology’s Lonsurf (a pill that combines two drugs, trifluridine and tipiracil) for patients with an advanced form of colorectal cancer who are no longer responding to other therapies. “The past decade has brought a new…
Health First Acquires Space Coast Cancer Centers A unit of Health First on Friday completed its acquisition of Space Coast Cancer Center, which had facilities in Titusville, Viera and Merritt Island. Former FLASCO President and Current FLASCO Board Member, Dr. Richard Levine, who founded and was president of the Space Coast Cancer Center, said the facilities…
“Your child needs a heart transplant.” Dr. Kasey Leger of Seattle Children’s Hospital – one of our most promising researchers – is working toward the day when parents of children who survived cancer will never have to hear those words. Can you imagine how you would feel after watching your child conquer cancer after enduring…
A new study released today from the Community Oncology Alliance (COA) finds that the 340B drug discount program is significantly larger than previous estimates have shown. Much of the growth is concentrated in oncology drugs for which 340B hospitals cost Medicare and beneficiaries more than community oncology clinics. [su_button url=”http://app.streamsend.com/c/24877027/900393/vmfceBi/SWYY?redirect_to=http%3A%2F%2Fwww.thestreet.com%2Fstory%2F13288335%2F1%2Fnew-study-reveals-340b-program-significantly-larger-than-previously-understood.html” target=”blank” style=”flat” background=”#f70032″ color=”#ffffff” size=”5″…
Dear coauthors our research project regarding genetic analysis of tumors in lung cancer patients with Hispanic origin was not only approved and selected to be presented as ORAL presentation at the 16th World Lung Cancer Congress where I had the honor to present on your behalf; but also it was chosen among more than 3,000…
ADCETRIS® (brentuximab vedotin) NEW INDICATION Dear Healthcare Professional: Seattle Genetics is pleased to announce FDA approval for use of ADCETRIS® (brentuximab vedotin) as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation treatment for patients with classical Hodgkin lymphoma (HL) at high risk of relapse or progression. The FDA decision was based on the positive results…
Florida Cancer Affiliates Names New Executive Director John E. Brown will lead Tampa, North Florida, and Ocala facilities, bringing extensive healthcare management experience to the practice New Port Richey, Fla. (September 10, 2015) – Florida Cancer Affiliates (FCA), a leading provider of advanced cancer care services in Florida and a practice in The US Oncology Network, has…
Boehringer Ingelheim has a website that provides information to assist with biomarker testing on Advanced Non Small Cell Lung Cancer. Explore “Let’s Test” for a wealth of resources. In the age of personalized medicine, oncologists can routinely order biomarker tests for their patients with advanced NSCLC—and use the results to consider more tailored treatment. Treatment decisions…
Florida Cancer Affiliates Expands Patient Access to Cutting-Edge Care with the Addition of Ferdy Santiago, MD Florida Cancer Affiliates (FCA), a community-based radiation oncology, medical oncology, and hematology practice announces that Ferdy Santiago, MD, has joined its practice and has begun seeing patients at its two centers at 8570 Granite Court, Fort Myers, Florida 33908…
Hematology and Oncology Consultants, PA Joins Florida Cancer Specialists & Research Institute Florida Cancer Specialists and Research Institute is pleased to announce that Hematology and Oncology Consultants, PA (HOC) is joining the practice, effective September 1, 2015. The alliance with HOC will add two clinical sites to the Florida Cancer Specialists’ network, extending services in…
FDA Approves Varubi (rolapitant) Treatment for Nausea and Vomiting from Chemotherapy The U.S. Food and Drug Administration approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis). Varubi is approved in adults in combination with other drugs (antiemetic agents) that prevent nausea and vomiting associated with initial and repeat courses of vomit-inducing (emetogenic…
Join the Effort to Stop Medicare Cuts to Radiation Oncology Contact Your Members of Congress Today! In its 2016 Physician Fee Schedule Proposed Rule, CMS is proposing overall Medicare cuts of three percent to radiation oncology services, and an even deeper six percent Medicare cut to freestanding radiation therapy centers. The proposed rule most…
Moffitt Cancer Center Researchers Develop Genetic Test that Predicts which Pancreatic Cancer Patients will Benefit from Surgery Pancreatic cancer, a highly lethal malignancy, is the fourth most common cause of cancer-related mortality in the United States. Approximately 25 percent of patients with early cancers undergo potential curative treatment with surgery and chemotherapy. Unfortunately, only about…
NCCN Publishes New Patient Education Resources for Kidney Cancer NCCN has published the NCCN Guidelines for Patients® and NCCN Quick Guide™ for Kidney Cancer, the newest addition to the library of NCCN Guidelines for Patients. Kidney Cancer is among the 10 most diagnosed cancers in both men and women in the United States, and it…
FDA approves Promacta (eltrombopag) to Treat Low Blood Platelet Count in Pediatric Patients The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called chronic immune thrombocytopenic purpura (ITP). Promacta can be used in…
Grand Opening on September 4, 2015 Dr. Jose Sarria has been the Chief of the Pain Medicine Service at Moffitt Cancer Center in Tampa since 2005. During this time, he became aware of a pressing need for dedicated pain and symptom management of cancer patients and particularly of cancer survivors, a growing population that frequently…
[su_list icon=”icon: check” icon_color=”#1243fe”] FDA Approval Based on the Phase 3 AETHERA Clinical Trial Results- AETHERA Trial Also Converts Prior Accelerated Approval to Regular Approval in Treatment of Classical Hodgkin Lymphoma Patients who Fail Autologous Hematopoietic Transplantation or who Fail at Least Two Prior Multi-Agent Chemotherapy Regimens and are Not Autologous Hematopoietic Transplantation Candidates Label…
Florida Cancer Specialists & Research Institute (FCS), is pleased to announce that Steven B. Newman, MD, has joined Florida Cancer Specialists and will be seeing patients at the FCS cancer center at Napa Ridge, located at 6360 Pine Ridge Road – Suite 201, Naples, FL 34119.Dr. Steven B. Newman has over 30 years experience as…
FLASCO Wants To Hear Your Step Therapy Story FLASCO is working with other health care organizations to encourage Florida lawmakers to address the negative impact of Step Therapy policies. We are currently looking for stories about barriers and challenges to navigating Step Therapy and fail-first policies to share with the media. If you have any…
Home Health Physician Certification Letter 05 06 2015 CMDs (Source: Contractor Medical Directors, Home Health/Hospice Medicare Contractors) Medicare has changed the physician documentation requirements for certification of home health care for dates of service effective January 1, 2015. While clinicians still need to certify benefit eligibility and a face to face encounter is still required,…
Myriad’s myPlan® Lung Cancer Myriad’s myPlan® Lung Cancer is a new RNA 46-gene expression signature based on cell cycle progression (CCP) genes —the genes that regulate cell division. myPlan Lung Cancer measures the expression levels of specific genes in combination with pathological stage to predict the 5-year risk of lung cancer death in patients with…
The Florida Department of Health is hosting a Cancer Research Symposium for the general public, designed to highlight and explain research funded through the Bankhead-Coley Cancer Research Program and the James and Esther King Biomedical Research Program. When: Friday, September 18, 2015 Where: University of Central Florida – College of Medicine, Orlando, Florida Click here to…
AKYNZEO® (netupitant/palonosetron) Florida Society of Clinical Oncology (FLASCO) News Flash In 2014, Eisai launched AKYNZEO (netupitant/palonosetron), a dual-action, single-dose oral antiemetic for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO is an oral fixed combination of…
Dr. Rakesh Rohatgi Merges His Practice With Florida Cancer Specialists & Research Institute Tri-County Hematology & Oncology Joins FCS Fort Myers, FL – August 3, 2015 . . .Florida Cancer Specialists & Research Institute , is pleased to announce that Rakesh Rohatgi, MD, is merging his practice (Tri-County Hematology & Oncology) with Florida Cancer Specialists…
Dr. Shilpa Oberoi Joins Florida Cancer Specialists & Research Institute in Ocala Cancer Center Florida Cancer Specialists & Research Institute, is pleased to announce that Shilpa Oberoi, MD, has joined Florida Cancer Specialists and will be seeing patients at the FCS cancer center in Ocala, located at 1630 SE 18th Street, Suite 602, Ocala, FL 34471.Dr….
Florida Cancer Affiliates Acquires Radiation Oncology Facility in Panama City Panama City, Fla. (August 4, 2015) – Florida Cancer Affiliates (FCA), a practice in The US Oncology Network, acquired a radiation oncology facility in Panama City. The acquisition allows the medical oncologists of FCA to offer a full range of both medical oncology and…
Univita Termination with All Statewide Medicaid Managed Care Plans The Statewide Medicaid Managed Care (SMMC) plans will no longer contract with Univita for home health, durable medical equipment (DME) or intravenous therapy for their Medicaid members. Providers should continue providing services to enrollees during the transition period for any services that were previously authorized or…
© 2021 FLASCO | Premium Website Design by The HDG
